Introduction {#s001}
============

Hepatitis C virus (HCV) infection is a blood-borne communicable disease that, in perhaps 20% of cases, results in a chronic disease, spanning an "indolent course."^[@B1]^ The sequela of HCV infection ranges from acute to chronic forms of liver disease, cirrhosis, and liver cancer.^[@B2]^ The HCV infection increases the risk of liver-related negative health outcomes. Patients may experience jaundice, dark urine, and nonspecific symptoms such as nausea, fatigue, and anorexia.^[@B3],[@B4]^ The HCV infection can result in several degrees of liver fibrosis and damage (cirrhosis).

The level of liver damage is classified based on the grade of inflammation and the stage of fibrosis (F0--F4, where F0 mild hepatitis/no fibrosis), depending on the extent of damage to and inflammation of the liver.^[@B5]^ Patients in the compensated cirrhosis (F4) do not experience symptoms of hepatitis, and have a significantly higher survival rate than those with decompensated cirrhosis.^[@B6]^

More than 2.7--3.9 million people with HCV infection live in the United States, and the disease causes long term decreased health related quality of life.^[@B4],[@B7],[@B8]^ A majority of these cases are prevalent rather than incident.^[@B16]^ The mortality due to HCV infection now exceeds human immunodeficiency virus in cause specific mortality.^[@B4],[@B17]^ Mortality due to HCV infection and liver cancer is predicted to increase, corresponding with the duration of infection.^[@B18]^

It was forecasted that although the incidence of HCV infection declined during the 1990s, individuals infected for more than 20 years would increase substantially before cresting in 2015.^[@B19]^ Due to lack of HCV screening of blood supplies before 1992, individuals who have had blood transfusions/exposure may be at a higher risk for HCV.^[@B20]^ The peak of HCV infection prevalence occurs in the population younger than 55 years and disproportionally affects the poor.^[@B21],[@B22]^

Treatment to reach sustained virologic response is desirable as this reduces the risk for the noted sequelae of HCV infection.^[@B10]^ Sustained virologic response is attained when the hepatitis C viral RNA cannot be detected in the patient\'s bloodstream for 6 months.^[@B23],[@B24]^ Length of treatment for peginterferon and ribavirin regimens can be 48 weeks, with weekly peginterferon injections and ribavirin pills taken once daily, orally.^[@B25]^ However, traditional peginterferon/ribavirin therapies pose many adverse side effects that are difficult to tolerate, and many patients do not complete the therapy.^[@B26]^ A new wave of treatments for HCV infection entered the market, with the approval of direct acting antivirals (DAAs) by the Food and Drug Administration. Currently approved DAA treatments include simeprevir, sofosbuvir, ledipasvir, ombitasvir/paritaprevir/ritonavir with dasabuvir, daclatasvir--sofosbuvir, elbasvir--grazoprevir, and most recently, sofosbuvir--velpatasvir.^[@B4],[@B27]^

Before the newly approved oral DAA agents, most newly detected cases of HCV infection did not prompt antiviral medication due to side effects and limited efficacy of peginterferon/ribavirin regimens. Health disparities arise since the disease progresses slowly and chronic HCV-infected patients often play a waiting game for treatment, either due to efficacy or affordability of effective treatments, putting health outcomes at risk.

Risk of HCV infection and subsequent health disparities are higher for certain populations, including low income.^[@B30],[@B31]^ The presence of HCV infection was found to be associated with Medicaid and public insurance usage.^[@B32]^ There will be a reduction in the number of low-income individuals who are uninsured, as with the Affordable Care Act there is increased eligibility for Medicaid services and coverage.^[@B31],[@B33],[@B34]^ This results in a large number of HCV-infected individuals who qualify for Medicaid.^[@B34]^ In addition, HCV infection screening/testing for high-risk patients is usually considered part of routine preventive services in non-grandfathered traditional Medicaid plans^[@B15]^; the Department of Health and Human Services is encouraging HCV testing^[@B35]^ and screening initiatives.

The number of Medicaid beneficiaries with HCV infection is high, and the number is rising, as the proportion of new Medicaid beneficiaries identified as infected with HCV will continue to increase.^[@B31],[@B33]^ There are 377,000 Medicaid beneficiaries who are HCV positive (all HCV genotypes), reported in 2013.^[@B31]^ In 2015, the payer forecasts that the number of HCV-infected Medicaid beneficiaries will be from 401,390 to 444,010.^[@B31]^ Hence, the Medicaid population is at greater risk; treatment of HCV infection is a priority for Medicaid.

However, healthcare access to these newer, efficacious treatments is reduced, due to inadequate or lack of coverage of DAA medication. Sofosbuvir has been considered a nonpreferred drug on the tiered formularies in a majority of Medicaid programs; many states also consider liver disease severity/presence of cirrhosis as a criteria for coverage of DAA medications.^[@B30],[@B36]^ Restricting treatment coverage has negative consequences on health of patients, public health of the population, opportunities for reduction of transmission among Medicaid beneficiaries, and treatment affordability/availability.^[@B37],[@B38]^

Many dimensions of HCV health disparities influence access to DAA treatment, including socioeconomics, availability of/access to care, and health insurance coverage. Individuals with inadequate health insurance coverage, as often occurs with Medicaid, have a lower chance of receiving appropriate medical care, and are more likely to have poor health status.^[@B39]^ Furthermore, several barriers arise when considering access to services---including high costs/low affordability of services/treatment, lack of insurance coverage of services (Healthy people, 2020).

Such barriers lead to preventable hospitalizations and negative health outcomes, delays in care, and unmet preventive services.^[@B39]^ In the case of HCV patients on Medicaid, lack of coverage for DAA medications leads to cases of potentially preventable negative liver-related health outcomes, treatments for liver cancer, and liver transplantations.

Health outcomes for HCV-infected Medicaid patients are already at a disadvantage. What would happen if you introduce DAA as a treatment, compared to current options for treatment? This is further explored in this study.

Materials and Methods {#s002}
=====================

The objective of this study was to evaluate the impact of HCV treatment regimens on outcomes of care for HCV-infected Medicaid beneficiaries without cirrhosis/liver disease scarring. Specifically, this study aimed to compare what happens to a cohort of patients without cirrhosis on Medicaid, and follow such a cohort over 10 years.

A cohort analysis was performed to evaluate the changes in cirrhosis, hepatocellular carcinoma, and liver transplantation with use of HCV treatments in Medicaid beneficiaries with HCV, and was followed over a period of 10 years. The cohort of Medicaid beneficiaries used a sample generated from published literature. The target population was the noninstitutionalized Medicaid population in the United States with a diagnosis of HCV infection. The data source is from published literature^[@B31]^ and publically available reports.^[@B15]^ The model considered 72,164 patients with HCV with cirrhosis on Medicaid, using data from public literature estimates,^[@B40]^ and age/genotype distributions of HCV. The study cohort was limited to Medicaid beneficiaries, 55 years and younger.

The National Average Drug Acquisition Cost values, as published by Mediciad,^[@B41]^ as well as wholesale cost were used for medication costs of American Association for the Study of Liver Diseases and the Infectious Diseases Society of America^[@B42]^ recommended treatments for HCV genotype 1a patients without cirrhosis. The treatments considered in this cohort analysis were ribavirin, peginterferon, sofosbuvir, simeprevir--sofosbuvir, sofosbuvir--velpatasvir, ombitasvir/paritaprevir/ritonavir, and dasabuvir. Furthermore, the effectiveness of each DAA treatment was extracted from published articles on clinical trials. [Table 1](#T1){ref-type="table"} illustrates the data used in the cohort analysis.

###### 

**Cohort Analysis: Values for Simulated Cohort**

  Input value/variable                                   References                                                           Base case value (range)/probabilities
  ------------------------------------------------------ -------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Rate variable: treatment response rate (SVR reached)                                                                        
   No treatment                                          ^[@B43]^                                                             1% (0.7--1.7%)
   Peginterferon--ribavirin                              Pegasys, Pegintron, Copegus, Rebetol                                 41% (38--44%)
   Elbasvir--grazoprevir, 12 weeks                       C-EDGE TN                                                            92% (94%)
   Harvoni (sofosbuvir--ledipasvir), 12 weeks            ION 1,3; NEUTRINO trial; ION 1, double blind; NEUTRINO, open label   96% (89--100); Gilead'16; range---genotype 1 Rx naive NC; ION 1, 96--100; ION 3, 95--98; NEUTRINO, 89--95
   Simeprevir--sofosbuvir without ribavirin, 12 weeks    ION 1,3; NEUTRINO trial; ION 1, double blind; NEUTRINO, open label   97% (97%); Base case---treatment naive, noncirrhosis genotype 1, range---genotype 1a
   Viekira Pak-ribavirin 12 weeks                        Pearl IV; Saphire I                                                  95.3% (93--97.6%)
   Daclatasvir--sofosbuvir                               ALLY-1                                                               96.4%
  Transition probabilities for cohort                                                                                         
   F3 to F4                                              ^[@B43]^                                                             0.116
   F4 with SVR to decompensated cirrhosis                ^[@B43]^                                                             0.008
   F4 without SVR to decompensated cirrhosis             ^[@B43]^                                                             0.039
   F4 with SVR to liver cancer                           ^[@B43]^                                                             0.005
   F4 without SVR to liver cancer                        ^[@B43]^                                                             0.014
   Decompensated cirrhosis to liver cancer               ^[@B43]^                                                             0.068
   Decompensated cirrhosis to liver transplant           ^[@B43]^                                                             0.023

  Treatment cost/day                                                                                    \$
  --------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------
   Pegylated interferon-- ribavirin                   Medicaid National Average Drug Acquisition Cost   Pegylated interferon (pegasys proclick): 1685.5 (1264.15--2106.8); ribavirin: 0.87 (0.66--1.1)
   Elbasvir--grazoprevir                              Medicaid National Average Drug Acquisition Cost   Elbasvir--grazoprevir: 650 (487.5--812.5)
   Sofosbuvir--velpatasvir                            ^[@B29]^                                          Sofosbuvir--velpatasvir: 890 (667.5--1112.5)
   Sofosbuvir--ledipasvir                             Medicaid National Average Drug Acquisition Cost   Sofosbuvir--ledipasvir: 1091.2 (818.4--1364.0)
   Simeprevir--sofosbuvir                             Medicaid National Average Drug Acquisition Cost   Sofosbuvir: 981.5 (736.13--1226.9)
                                                                                                        Simeprevir: 781.2 (585.96--76.5)
   Ombitasvir--daclatasvir--paritaprevir--ribavirin   Medicaid National Average Drug Acquisition Cost   Viekira Pak: 243.5 (182.65--304.4)
                                                                                                        Ribavirin: 0.9 (0.7--1.1)
   Daclatasvir--sofosbuvir                            Medicaid National Average Drug Acquisition Cost   Sofosbuvir: 981.50 (736.1--1226.9)
                                                                                                        Daclatasvir: 723.625 (542.74--904.53)

  Cost: total/all-cause healthcare cost/year                                     \$/year
  ------------------------------------------------------------ ----------------- -------------------------------------------------------------------
   HCV infection monitoring                                    ^[@B31],[@B43]^   14,915.00 (14464--16686)
   Decompensated cirrhosis                                     ^[@B31],[@B43]^   41,943.00 (38670--44936)
   Compensated cirrhosis                                       ^[@B31],[@B43]^   16,911.00 (15313--26354)
   Liver cancer                                                ^[@B31],[@B43]^   58,208.00 (50878--66116)
   Liver transplant+medical cost, first and subsequent years   ^[@B31],[@B43]^   190,995.00 (182,973--199,017)
                                                                                 SD=8022; subsequent years: 54,885.00 (50,476--59,294); SD=4409.00

F0--F3, where F0 is mild hepatitis; HCV, hepatitis C virus; SD, standard deviation; SVR, sustained virological response.

These American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommended medications were evaluated in the context of a watch/wait scenario (no treatment for oncogenic disease) and peginterferon--ribavirin. Since DAAs are not fully covered for Medicaid patients due to high medication costs, peginterferon--ribavirin is considered as an alternative treatment option. Furthermore, since many providers are reluctant to treat patients with peginterferon--ribavirin due to side effects and low efficacy, a watch and wait strategy is often considered.

The cohort progressed through the natural history of HCV disease stages. The treatment is successful if the individual reaches sustained virologic response. All patients in the cohort analysis began at a baseline of HCV infection, without liver cirrhosis/scarring (F0--F3). The individual is treated, by one of the noted regimens, and either (1) reaches sustained virologic response or (2) fails to reach sustained virologic response. Patients who failed to reach sustained virologic response were modeled to be retreated in year 2; each individual in the Medicaid cohort had a 50% chance of retreatment, illustrating the implicit effects of access to care and affordability of DAA medications. If the patient reaches sustained virologic response from F0 to F3, the patient reaches a normal health status. If the patient does not reach sustained virologic response, the patient continues into disease progression stages of liver damage.

Each disease stage had a bivariate decision; the individual with liver damage may stay in the same health stage or progress. At each of the 10 years, each patient can progress from the following: • F0--F3 to F4/compensated cirrhosis liver damage state.• From F4 liver damage state to decompensated cirrhosis or liver cancer.• From decompensated cirrhosis state to liver cancer or liver transplantation.^[@B43],[@B44]^

Patients who are in liver cancer state can either continue with liver cancer or move to liver transplantation state.

Thus, liver transplantation, liver cancer, and decompensated cirrhosis are endpoints in the model. Each event in the natural history/disease progression occurs on a yearly basis. All treatment-naive patients were started at the same baseline and will continue through the natural history progression.

This study was based entirely on the use of published literature and costs. These are publicly available, published sources, which omit patient-level, personal identification information. The Medicaid National Average Drug Acquisition Cost data set is an aggregated, publically available data set on costs of medications. In addition, published literatures on HCV infection were used. Since there was no risk posed to human subjects in this research, this study met the exempt status by the University of Texas Health Science Center Committee for Protection of Human Subjects.

Over the 10-year period of time, the all-cause healthcare costs in the Medicaid HCV cohort for liver-related outcomes (decompensated cirrhosis, compensated cirrhosis, hepatocellular carcinoma, and liver transplantation) that were averted by each treatment were evaluated. The Medicaid cohort\'s disease progression through the HCV natural stages was also determined.

Results {#s003}
=======

The cohort analysis of Medicaid beneficiaries without cirrhosis indicated that patients on DAA treatments had lower incidence of liver-related outcomes, as well as all-cause healthcare costs. Since reaching treatment success results in reaching a healthy state, only individuals who do not reach sustained virologic response are at a higher risk for liver-related conditions. Thus, when following the cohort after the 10-year period, the number of individuals and the associated costs of liver-related outcomes are low in patients on DAA treatments. Since treatment success prevents disease progression of HCV natural history, patients without cirrhosis have reduced overall disease progression; among those in the cohort who progressed to end-stage liver disease outcomes, most of the cohort was in early stages. This results in overall improved outcomes, lowered medical costs accrued, and higher savings/averted medical costs.

Furthermore, the cohort analysis, presented in [Table 2](#T2){ref-type="table"}, of Medicaid beneficiaries illustrated that DAA treatments resulted in the lowest number of individuals in end-stage liver disease-related outcomes, over the 10-year progression of the cohort, as in [Table 2](#T2){ref-type="table"}. Approximately 600 individuals were in decompensated cirrhosis, after the 10-year time period, while with peginterferon--ribavirin treatment, there were 3334 individuals with decompensated cirrhosis.

###### 

**Cohort Analysis: Yearly Breakdown of Health Outcomes of Medicaid Beneficiaries Without Cirrhosis**

                                                  Year 1        Year 2        Year 3        Year 4        Year 5        Year 6        Year 7        Year 8        Year 9        Year 10
  ----------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  No treatment                                                                                                                                                                  
   F3                                             72163.52      63157.80519   55831.49978   49355.04581   43629.86049   38568.79668   34094.81626   30139.81758   26643.59874   23552.94128
   Compensated cirrhosis                          0             8287.675794   6887.058584   12998.49845   18034.76335   22323.23621   25614.0851    28211.53728   30212.54464   31701.93723
   DCC                                            0             0             323.2193559   562.4016793   1018.164566   1628.867361   2351.246644   3136.232518   3951.085313   4769.82579
   HCC                                            0             0             116.0274611   229.7840991   440.8150276   744.9043039   1130.728642   1603.98146    2148.047534   2753.775059
   Liver transplantation, year 1/incident cases   0             0             0             12.07514363   22.12660259   41.05038613   67.26012147   99.30781849   136.2926063   176.7968636
  Peginterferon--ribavirin                                                                                                                                                      
   F3                                             63811.60285   11596.09724   10250.94996   9061.839768   8010.666354   7081.429057   6259.983287   5533.825225   4891.901499   4324.440925
   Compensated cirrhosis                          0             2456.217073   1214.967775   2339.684679   3266.854804   4054.168734   4660.743562   5139.882215   5509.392183   5784.854972
   DCC                                            0             0             95.79246586   134.4590947   213.4710196   321.4524941   450.3128978   591.103423    737.7684179   885.497787
   HCC                                            0             0             34.38703903   56.534994     96.17239819   152.5774988   223.8012234   310.7208614   410.4454107   521.3273372
   Liver transplantation, year 1                  0             0             0             3.578708276   5.353958938   8.756729378   13.49650732   19.30924558   26.02421318   33.38649004
  Sofosbuvir--velpatasvir                                                                                                                                                       
   F3                                             66548.76516   3333.022895   2946.392239   2604.610739   2302.475894   2035.38869    1799.283602   1590.566704   1406.060966   1242.957894
   Compensated cirrhosis                          0             1448.636049   309.8529452   635.2122389   903.680836    1130.062085   1306.273882   1445.758264   1553.638814   1634.399029
   DCC                                            0             0             56.49680591   63.43986143   80.32944864   108.2630214   142.4835078   180.46219     220.424703    260.9579687
   HCC                                            0             0             20.28090468   27.64939253   39.75029875   56.27422101   76.96692616   101.864962    130.3024081   161.830135
   Liver transplantation, year 1/incident cases   0             0             0             2.110662723   2.565092514   3.437589269   4.741018333   6.355797725   8.225228849   10.28186449
  Elbasvir--grazoprevir                                                                                                                                                         
   F3                                             66548.76516   3746.336692   3311.761636   2927.597286   2587.996001   2287.788465   2022.405003   1787.806023   1580.420524   1397.091743
   Compensated cirrhosis                          0             1538.215105   353.0496558   718.5023738   1020.023033   1274.322431   1472.166804   1628.740944   1749.803172   1840.392385
   DCC                                            0             0             59.99038908   68.30020025   90.1064746    121.6876837   160.3126793   203.1387308   248.1740031   293.8324926
   HCC                                            0             0             21.53501146   29.69565264   43.21127339   61.89038519   85.20684499   113.3101686   145.3935688   180.9509027
   Liver transplantation, year 1/incident cases   0             0             0             2.241179407   2.758730711   3.800899851   5.274432133   7.095465423   9.204597554   11.52374482
  S-ledipasvir                                                                                                                                                                  
   F3                                             66548.76516   3400.355319   3005.914102   2657.228067   2348.989611   2076.506816   1835.632025   1622.69871    1434.46566    1268.067643
   Compensated cirrhosis                          0             1477.900828   316.1124732   648.044548    921.9366427   1152.891157   1332.662716   1474.964907   1585.024817   1667.416519
   DCC                                            0             0             57.63813228   64.72144869   81.95223273   110.4501086   145.3619038   184.1078165   224.8776366   266.2297395
   HCC                                            0             0             20.69061159   28.20795474   40.55331874   57.41105081   78.52178189   103.9227981   132.9347264   165.0993641
   Liver transplantation, year 1/incident cases   0             0             0             2.153301506   2.61691151    3.507034102   4.83679453    6.484195064   8.391391704   10.4895747
  Simeprevir--sofosbuvir                                                                                                                                                        
   F3                                             66548.76516   3318.464735   2933.522826   2593.234178   2292.419013   2026.498408   1791.424592   1583.61934    1399.919496   1237.528835
   Compensated cirrhosis                          0             1463.195469   307.3925494   631.389392    898.7409189   1123.988866   1299.491272   1438.423487   1545.886886   1626.345542
   DCC                                            0             0             57.06462328   63.86005198   82.67297354   110.2006288   144.0079374   181.5833747   221.1578036   261.322032
   HCC                                            0             0             20.48473656   27.84923717   39.91720271   56.52464967   77.21952209   102.1161588   130.5171107   161.9775733
   Liver transplantation, year 1/incident cases   0             0             0             2.131875798   2.582750683   3.4981665     4.795600449   6.400963443   8.261063967   10.30731391
  Daclatasvir--sofosbuvir                                                                                                                                                       
   F3                                             66548.76516   3367.384755   2976.768123   2631.463021   2326.213311   2056.372567   1817.833349   1606.96468    1420.556777   1255.772191
   Compensated cirrhosis                          0             1472.001032   312.6005769   641.3378486   912.5966531   1141.166132   1319.223544   1460.173365   1569.19208    1650.809486
   DCC                                            0             0             57.40804024   64.37533107   83.52935204   111.5194505   145.8766596   184.0516018   224.2496673   265.0414387
   HCC                                            0             0             20.60801444   28.06384868   40.29754713   57.14199432   78.13669544   103.3999701   132.2219073   164.1506975
   Liver transplantation, year 1/incident cases   0             0             0                           2.603186562   3.533076982   4.850627134   6.480630989   8.369185646   10.44661864
  Ombitasvir/paritaprevir/ritonavir/ribavirin                                                                                                                                   
   F3                                             66548.76516   3458.749614   3057.534659   2702.860639   2389.328805   2112.166663   1867.15533    1650.565312   1459.099736   1289.844166
   Compensated cirrhosis                          0             1488.282427   322.3359867   659.9261998   938.4819453   1173.254852   1356.083678   1500.801261   1612.724371   1696.505549
   DCC                                            0             0             58.04301464   65.33220378   85.12409503   113.9785983   149.3634851   188.6586714   230.0219815   271.9862316
   HCC                                            0             0             20.83595397   28.46214462   41.00521549   58.29219257   79.84679742   105.794814    135.4030288   168.2065435
   Liver transplantation, year 1/incident cases   0             0             0             2.168427496   2.641126472   3.598062805   4.953195463   6.629232053   8.570942001   10.70662672

DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma.

The cohort analysis revealed that progression of the patient through disease stages is affected by the treatment choice. DAA treatments resulted in a higher number of individuals who reached sustained virologic response; as in [Table 3](#T3){ref-type="table"}, within those who did not reach treatment success, DAA treatment illustrated there was a higher percentage of the Medicaid cohort that remained in earlier stage of disease. For DAA-based regimens, the number of individuals in decompensated cirrhosis progressed from ∼60 to 260, over the 10-year cohort analysis. In addition, as demonstrated in [Table 3](#T3){ref-type="table"}, DAA regimens showed that end-stage liver disease outcomes, such as liver transplantation, were low; after 10 years, the number of individuals with liver transplantation in the cohort increased by ∼20. Peginterferon--ribavirin regimens showed that cohort progression toward liver transplantation increased by 97 patients, after the 10-year period of time.

###### 

**Cohort Analysis--Year 10: Health Outcomes of Medicaid Beneficiaries Without Cirrhosis**

  Treatment regimen                             Number of individuals who reached SVR after treatment regimen completion   Total number of individuals in DCC at year 10   Total number of individuals in HCC at year 10   Total number of individuals progressing to liver transplantation at year 10
  --------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------------------------------------
  No treatment                                  718.0390212                                                                17417.82387                                     9052.036126                                     554.9095422
  Peginterferon--ribavirin                      21463.03262                                                                3334.065134                                     1771.579724                                     109.9058527
  Sofosbuvir--velpatasvir                       41572.28156                                                                1056.360701                                     594.6383436                                     37.71725391
  Elbasvir--grazoprevir                         40027.81508                                                                1185.552264                                     659.6587963                                     41.8990499
  Sofosbuvir--ledipasvir                        41067.71641                                                                1077.700886                                     606.6509947                                     38.47920311
  Simeprevir--sofosbuvir                        41321.25708                                                                1064.804802                                     596.1214544                                     37.97773475
  Daclatasvir--sofosbuvir                       41169.43703                                                                1078.643501                                     603.4126605                                     38.42803146
  Ombitasvir/paritaprevir/ritonavir/ribavirin   40888.72333                                                                1104.465267                                     617.0107364                                     39.26761301

Finally, considering the impact on health expenditures due to improved access to DAAs in Medicaid beneficiaries, as shown in [Table 4](#T4){ref-type="table"}, Sofosbuvir--velpatasvir also resulted in the lowest decompensated cirrhosis and hepatocellular carcinoma-related healthcare cost per person, over the 10-year time frame the cohort was followed. The next treatment option that resulted in lowered negative liver-related outcomes as well as reduced health expenditures is elbasvir--grazoprevir and sofosbuvir--ledipasvir.

###### 

**Cohort Analysis--Year 10: Healthcare Costs of Medicaid Beneficiaries Without Cirrhosis**

  Treatment regimen                             HCC healthcare costs per 10 years   HCC healthcare costs per person   DCC healthcare costs per 10 years   DCC healthcare costs per person   Liver transplantation (first year/total incident cases) healthcare costs per 10 years   Liver transplantation (first year/total incident cases) healthcare costs per person
  --------------------------------------------- ----------------------------------- --------------------------------- ----------------------------------- --------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  No treatment                                  \$435,443,320.89                    \$6,034.12                        \$645,476,757.68                    \$8,944.64                        \$92,292,676.44                                                                         \$1,278.94
  Peginterferon--ribavirin                      \$84,830,588.40                     \$1,175.53                        \$124,014,066.74                    \$1,718.51                        \$18,347,552.27                                                                         \$254.25
  Sofosbuvir--velpatasvir                       \$28,178,598.18                     \$390.48                          \$39,633,801.65                     \$549.22                          \$6,346,233.61                                                                          \$87.94
  Elbasvir--grazoprevir                         \$31,295,432.78                     \$433.67                          \$44,448,636.24                     \$615.94                          \$7,044,797.83                                                                          \$97.62
  Sofosbuvir--ledipasvir                        \$28,747,851.20                     \$398.37                          \$40,434,468.20                     \$560.32                          \$6,474,437.74                                                                          \$89.72
  Simeprevir--sofosbuvir                        \$28,246,885.35                     \$391.43                          \$39,964,659.74                     \$553.81                          \$6,391,230.83                                                                          \$88.57
  Daclatasvir--sofosbuvir                       \$28,596,628.34                     \$396.28                          \$40,478,671.63                     \$560.93                          \$6,466,297.87                                                                          \$89.61
  Ombitasvir/paritaprevir/ritonavir/ribavirin   \$29,248,963.84                     \$405.32                          \$41,437,692.90                     \$574.22                          \$6,606,249.52                                                                          \$91.55

Within the Medicaid cohort of HCV patients, sensitivity analysis concerning the retreatment of hepatocellular cancer during the second year of follow-up was conducted, to illustrate the effects of retreatment. The retreatment of all or none of the patients who did not reach treatment success was analyzed. The retreatment of all eligible patients (those who did not reach treatment success), illustrated higher savings/averted medical costs and improved outcomes. Thus, compared to not retreating the cohort, it is evident that there is a pattern of reduced number of negative health outcomes for patients, which arises in retreatment of all eligible cohort patients.

Discussion {#s004}
==========

This study demonstrates the importance of treatment with DAAs for patients in the early stages of the disease (without cirrhosis) to prevent cirrhosis and the negative outcomes associated with HCV infection. Furthermore, the result of this cohort analysis has many health equity implications for Medicaid beneficiaries with HCV, especially in terms of improved access to DAA medications within Medicaid.

Currently, many Medicaid beneficiaries do not have access to DAAs, as coverage is restricted toward patients with cirrhosis/liver disease. It becomes evident that the primary impact of DAAs on patients with and without cirrhosis is driven by the number of individuals in earlier stages of the disease.^[@B45]^ The risk of liver-related disease is higher in patients with cirrhosis, as reaching treatment success results in continued disease progression, not normal health status; thus, the liver cancer healthcare costs are higher in patients with cirrhosis, compared to those without cirrhosis. However, this indicates that DAAs are more cost saving in the case of patients without cirrhosis (early stage). Since DAAs are highly effective, and reaching sustained virologic response results in avoidance of disease progression of HCV natural history, the costs associated with a cohort of patients treated with DAAs are low, emphasizing the importance of early treatment.

Essentially, treatment and HCV disparities influence health services. Thus, the results of this study can be placed in the context of conceptual frameworks/theory of the Andersen--Aday model.

The Andersen--Aday model explains health services utilization as a function of population and delivery system characteristics. The Andersen--Aday model illustrates disparities and health equity issues in HCV treatment utilization, where age, gender, race/ethnicity, income, education, occupation, consumer behavior, place of birth/citizenship status, comorbidities predispose certain groups as vulnerable to HCV. Insurance status/coverage, regular source of care, screenings/tests are the major components of the delivery system that enable utilization of services and treatment. Along with predisposing and enabling factors, perceived/medical need affects the realized access---that is, actual use of care, which in turn improves health outcomes.

Health equity then needs to be considered in terms of access to DAAs/health services---for prescription. The implications of this analysis aids in the clarification of prescription drug coverage for Medicaid beneficiaries and current restrictions.^[@B38]^ Coverage for sofosbuvir--ledipasvir in Medicaid patients is restricted by physician type, for 2/3rds of states.^[@B30]^ Another manner for denying DAA is to restrict its prescription to specialists, and not by general practitioners or primary care physicians.^[@B30]^ The 30 states that cover sofosbuvir for treatment of HCV infection have prior authorization criteria that require sofosbuvir to be prescribed by a gastroenterologist, hepatologist, or liver infectious disease specialist.^[@B30],[@B36]^ Lack of an usual source of care can infringe on access to care and treatments.^[@B46]^ Difficulties with entry to the healthcare system, as well as accessing specialist care in an available location, often occur to patients with inadequate coverage, or those on Medicaid. In certain states, coverage for DAAs is also restricted by limits on weekly refills, the investigation of prior pharmacy refill records to estimate patient adherence; these restrictions may not be feasible for patients due to transportation limitations.^[@B36]^

Furthermore, the achievement of health equity for HCV patients is dependent on not limiting access to treatment based on disease severity.

The Centers for Medicare and Medicaid Services have issued a letter to states on the health disparity issues that arise with prescription coverage; the agency is concerned that managed care plans are more stringent than fee for service Medicaid regarding the coverage of DAAs.^[@B47]^ The uptake of these medications is low due to the issue of affordability and coverage, especially for Medicaid patients.^[@B37]^ The Medicare/Medicaid dual eligible populations, who have compounded risk factors for HCV infection due to age and low-income status, are especially at risk for reduced access to medications due to affordability.

Since the use of DAAs provides strong cost savings, states may also want to review policies and consider changing those that otherwise interfere with access, such as lack of network specialists and associated stigma from approval criteria. As shown in a study of HCV screening and treatment in southeast Michigan, Medicaid patients who screened positive for HCV were more likely to have inadequate care coordination and linkage between providers.^[@B48]^

The goal of eliminating HCV is precluded by screening, delivery coordination, and disparities in clusters of vulnerable populations. The combination of a scale up strategy with a physician-based promotion of DAA treatment as prevention would address gaps in care.^[@B49],[@B50]^ The advent of new pangenotypic treatments, such as sofosbuvir--velpatasvir, and coordination among Medicaid stakeholders and multiple payers create a direction toward improved care delivery and a quick scale-up strategy for treatment.^[@B50]^

Patients are often facing drug authorization issues through Medicaid^[@B30],[@B46],[@B51],[@B52]^; due to issues with authorization and coverage, the public health of the community is at risk, with the avoidance of the medication costs associated with a cure for the viral infection,^[@B38]^ the public health benefit of addressing health disparity in hepatitis C needs to be balanced.^[@B50]^ Furthermore, unintended consequences in the entire healthcare system may be a result of changes in pharmacy benefits for Medicaid patients.^[@B46],[@B50]^ In addition, with changes in approval of coverage, costs of physician paperwork burden for prior authorization, documentations of treatment history, and appeals of medical necessity will change, further affecting delay in treatments and potential public health benefit from reduced transmission and individual health outcome risks.

The results of this study indicate that despite real-world variation in treatment discontinuation, implementation of coverage for DAAs results in savings for Medicaid. One of the biggest critiques of Medicaid coverage for DAAs is that patients must be adherent to treatment regimens although there is no strong evidence that discontinuation affects outcomes, in HCV interferon-based treatments^[@B46],[@B52]^; currently, an area for future research is to evaluate whether this is consistent in oral DAA medications.^[@B46],[@B52]^ The sensitivity analysis conducted in this study shows that even when there is 8.3% treatment discontinuation, there is still overall benefit to Medicaid, as the benefit of treatment is averaged out.

The Office of Health Equity has recognized the importance of the disparities that exist within HCV and the contribution of this disease toward advanced liver disease outcomes, with the development of the Hepatitis C--Advanced Liver Disease Disparities Dashboard, using data from the VA system.^[@B57]^ The dashboard allows for views of vulnerable areas for targeting interventions to improve health disparities within the VA population.^[@B57]^ Building on this work with additional vulnerable populations, especially Medicaid and dual eligible Medicare/Medicaid beneficiaries, would aid in increasing the coordination among siloed physician groups and payers, as well as the availability of evidence for decision makers. Increasing access to information regarding the impact of disparities in care and treatment would improve targeting of care.

Conclusion {#s005}
==========

The Medicaid population is at a high risk for HCV infection, due to socioeconomic burdens and lack of financial resources.^[@B30],[@B31]^ In this study, we have discussed how increased coverage of DAA treatments can improve efforts toward reduced risk of long-term negative health outcomes, especially liver cancer, for patients with HCV. Efforts toward increased DAA coverage and affordability are urgent, as early treatment of individuals with early stages of HCV can aid the burden of disparities. The high prevalence in HCV, especially in vulnerable and disproportionately affected populations such as Medicaid-insured African Americans, Asian Americans and Pacific Islanders, Hispanics and Latinos, and Native Americans, means that this disease is a challenge from both health outcome and cost long-term perspectives (health affairs).

With the looming impact of DAA treatment on Medicaid and health disparities, this study provides a foundation for the coordinated actions of decision makers, providers, and Medicaid analysts to value treatments in the context of long-term prevention, and management of HCV toward the goal of health outcomes and equity.^[@B58]^
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